Tivozanib hydrochlorideProduct ingredient for Tivozanib

Name
Tivozanib hydrochloride
Drug Entry
Tivozanib

Renal cell carcinoma (RCC) is responsible for 3% of cancer cases2 and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.10 Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies. It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.9

Accession Number
DBSALT002078
Structure
Synonyms
Tivozanib HCl / Tivozanib HCl hydrate / Tivozanib hydrochloride / Tivozanib hydrochloride hydrate / Tivozanib hydrochloride monohydrate
UNII
8A9H4VK35Z
CAS Number
682745-41-1
Weight
Average: 509.34
Monoisotopic: 508.0916398
Chemical Formula
C22H22Cl2N4O6
InChI Key
RQXMKRRBJITKRN-UHFFFAOYSA-N
InChI
InChI=1S/C22H19ClN4O5.ClH.H2O/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18;;/h4-11H,1-3H3,(H2,25,26,27,28);1H;1H2
IUPAC Name
1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea hydrate hydrochloride
SMILES
O.Cl.COC1=C(OC)C=C2C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=NC2=C1
ChemSpider
9722757
ChEMBL
CHEMBL2105756
Predicted Properties
PropertyValueSource
Water Solubility0.0521 mg/mLALOGPS
logP4.25ALOGPS
logP4.22Chemaxon
logS-3.9ALOGPS
pKa (Strongest Acidic)8.27Chemaxon
pKa (Strongest Basic)5.89Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area107.74 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity120.85 m3·mol-1Chemaxon
Polarizability44.2 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon